Navigation Links
Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs
Date:9/14/2007

Long-Term Outlook More Favorable as Drugs from Eli Lilly and GlaxoSmithKline Will Drive the Market in 2016, According to a New Report

from Decision Resources

WALTHAM, Mass., Sept. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the patent expiries of Merck's Proscar and Boehringer Ingelheim/Astellas's Flomax/Harnal, combined with the limited emergence of new therapies, will cause a 23% decline in sales of therapies to treat benign prostatic hyperplasia over the next five years.

The new Pharmacor report entitled Benign Prostatic Hyperplasia finds that the market to treat the disease is dominated by two drug classes-alpha blockers and 5-alpha-reductase inhibitors-which make up 93% of drug sales in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. The report finds that the patent expiries of Proscar and Flomax/Harnal will cause a significant decline in the overall benign prostatic hyperplasia market by 2011.

Although patent expiries will constrain the market in the near term, increases in the patient population, unmet need, and higher drug treatment rates from 2011 to 2016 will help create a favorable landscape for novel benign prostatic hyperplasia treatments.

"Eli Lilly's Cialis and GlaxoSmithKline's fixed-dose combination of tamsulosin and dutasteride, both of which are expected to launch for benign prostatic hyperplasia in the United States and in Europe by 2011, are the two most promising agents in the pipeline," said Greg Dwyer, analyst at Decision Resources. "The combined sales of these two drugs will represent nearly 30% of the total benign prostatic hyperplasia market in 2016."

To listen to an interview with Mr. Dwyer regarding the benign prostatic hyperplasia drug market, please visit the Find Out More section of the Decision Resources home page on September 17, 2007, at http://www.DecisionResources.com.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Indian Doctor granted US patent on organ regeneration
2. Dr Reddy’s Laboratories to challenge patents on drug
3. Yoga, ayurveda being documented to stop patent misuse
4. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
5. US Court Rules Against Lupin in Ramipril Patent Case
6. HIV Patients Opposes Patenting Of AIDS Drug
7. Provigil Patent Extension Accorded To Cephalon
8. AIDS Sufferers Protest against Proposed Patent for Tenofovir
9. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
10. Venus Remedies Files 5th International Patent Application
11. Patent for Seminal RNAi innovation Cleared in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
(Date:3/28/2017)... San Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... million people suffering from acne, access to quality care can be limited while the ... skincare company that offers customized prescription acne care for every customer online, today released ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & Clients ... to for the Toys for Tots Literacy Campaign at their Semi-Annual Graduation and Fundraiser ... $70 billion, the U.S. ranks at number 14 internationally in literacy. Statistically, a direct ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... be offered by the American Association of Integrative Medicine and available for application ... providers at the AutismOne 2017 Conference in Colorado Springs. , Ed Arranga, president ...
(Date:3/28/2017)... ... March 28, 2017 , ... The ... in Atlantic City March 13-16, was a busy spot this year. Liz Solovay ... discussed strategies for preventing outbreaks among camp communities during the upcoming 2017 camping ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... LONDON , March 27, 2017 ... require to better understand Eli Lilly and its partnering interests ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ... deal and company data. The report will be ...
(Date:3/27/2017)... March 27, 2017  A recent study at Shriners ... freestanding hospitals in the country dedicated to the treatment ... surgery, concluded that the Surfacide Helios ® UV-C ... in reducing bacterial pathogens not killed by the EVS ... at the American Burn Association,s 49th Annual Meeting in ...
(Date:3/27/2017)... 27, 2017  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" ... offer shares of common stock in an underwritten public ... with the Securities and Exchange Commission (the "SEC"). The ... there can be no assurance as to whether or ... the actual size or terms of the offering. Cryoport ...
Breaking Medicine Technology: